|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Symbicort[吸必擴] information |
|
|
|
製造商 |
AstraZeneca |
|
代理/經銷商 |
AstraZeneca |
|
成份 |
Per 160/4.5 Budesonide 160 mcg, formoterol fumarate dihydrate 4.5 mcg |
|
適應症 |
Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting β2-agonist) is appropriate. Symptomatic treatment of severe COPD & history of repeated exacerbation symptoms despite regular therapy with long-acting bronchodilators. |
|
用量 |
Asthma Maintenance therapy (with a separate rapid-acting bronchodilator): Adult & adolescents ≥12 years 1-2 inhalations bid. Max: 4 inhalations bid for adult ≥18 years. Children ≥6 years 1 inhalation bid. Max: 2 inhalations daily. Maintenance & reliever therapy (SMART): Adult & adolescents ≥12 years 2 inhalations once daily or 1 inhalation bid. Some patients may require a maintenance dose of 2 inhalations bid. Additional inhalations could be taken as needed in response to symptoms. Max: Not > 6 inhalations on single occasion. Total daily dose up to 12 inhalations (maintenance + reliever) may be used temporarily. COPD Adult 2 inhalations bid. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
注意事項 |
Thyrotoxicosis, pheochromocytoma, DM, untreated hypokalemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm or other severe CV disorders. Patients with prolongation of the QTc-interval. Pregnancy & lactation. Monitor growth of children on long term therapy. |
|
不良反應 |
Palpitation, oral candidiasis, headache, tremor, mild throat irritation, cough, hoarseness.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Itraconazole, ritonavir, β-adrenergic blockers, quinidine, disopyramide, procainamide, phenothiazines, terfenadine, MAOI, tricyclic antidepressant, levodopa, thyroxine, oxytocin, halogenated anesth, digitalis glycosides.
View more drug interactions with Symbicort[吸必擴] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Symbicort 160/4.5 定量粉狀吸入劑 |
|
|
Symbicort 320/9 定量粉狀吸入劑 |
|
|
|
Manufacturer: |
AstraZeneca |
|
Distributor: |
AstraZeneca |
|
|
|
|
|
